IGF-1: Old Growth Factor Shines as New Drug Target
Open Access
- 1 June 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 97 (11) , 790-792
- https://doi.org/10.1093/jnci/97.11.790
Abstract
Late last year, Pfizer launched a phase I trial of a new monoclonal antibody against cancer. The target: the insulin-like growth factor 1 (IGF-1) receptor. Pfizer's drug was the first in a cavalcade of such agents now in development, including both monoclonal antibodies and small molecules.Keywords
This publication has 0 references indexed in Scilit: